Horm Metab Res 2025; 57(04): 221-228
DOI: 10.1055/a-2538-3603
Review

46, XX DSD with Atypical Genitalia: Clinical Insights and Diagnostic Approaches

Manjiri Karlekar
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
,
Vijaya Sarathi
2   Endocrinology, Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, India (Ringgold ID: RIN75893)
,
Rohit Barnabas
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
,
Anurag Lila
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
,
Saba Samad Memon
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
,
Nalini Shah
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
,
1   Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, India (Ringgold ID: RIN29549)
› Author Affiliations

Abstract

Congenital adrenal hyperplasia (CAH) is a rare disorder with autosomal recessive inheritance; it was historically known as adrenogenital syndrome. Patients with virilizing forms of CAH and a 46,XX karyotype present with varied degrees of hyperandrogenism due to different genetic defects in the adrenal steroidogenesis pathway. This comprehensive review describes a simplified diagnostic approach for patients with atypical genitalia and 46, XX DSD. It highlights the importance of a detailed history and clinical examination, with specific pointers toward the etiological diagnosis. There is a need for utilizing standardized liquid chromatography/tandem mass spectrometry (LC-MS/MS) assays to accurately diagnose these disorders of steroidogenesis. Choosing appropriate molecular testing methods has significant implications for establishing the diagnosis and providing genetic counseling.

Supplementary Material



Publication History

Received: 02 January 2025

Accepted: 03 February 2025

Article published online:
05 March 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 
  • References

  • 1 Miller WL, White PC. A brief history of congenital adrenal hyperplasia. Horm Res Paediatr 2022; 95: 529-545
  • 2 Lewis RA, Klein R, Wilkins L. Congenital adrenal hyperplasia with pseudohermaphrodism and symptoms of Addison’s disease: clinical course following bilateral total adrenalectomy, with metabolic studies, pathologic findings and discussion of etiology. J Clin Endocrinol Metab 1950; 10: 703-715
  • 3 Hannah-Shmouni F, Chen W, Merke DP. Genetics of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2017; 46: 435-458
  • 4 Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med 2020; 383: 1248-1261
  • 5 Ahmed SF, Achermann J, Alderson J. et al. Society for endocrinology UK guidance on the initial evaluation of a suspected difference or disorder of sex development (Revised 2021). Clin Endocrinol (Oxf) 2021; 95: 818-840
  • 6 Mitami-Komo M, Saito R, Narumi-Wakayama H. et al. Clitoral preputial edema can be mistaken for clitoromegaly: a clinical analysis of ten cases. Front Endocrinol (Lausanne) 2023; 14: 1175611
  • 7 Shima R, Sawano K, Shibata N. et al. Timing of hyponatremia development in patients with salt-wasting-type 21-hydroxylase deficiency. Clin Pediatr Endocrinol 2020; 29: 105-110
  • 8 Al Alawi AM, Nordenström A, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency. Endocrine 2019; 63: 407-421
  • 9 Hinz L, Pacaud D, Kline G. Congenital adrenal hyperplasia causing hypertension: an illustrative review. J Hum Hypertens 2018; 32: 150-157
  • 10 Makiyan Z. Systematization of ambiguous genitalia. Organogenesis 2016; 12: 169-182
  • 11 Abali ZY, Guran T. Diagnosis and management of non-CAH 46,XX disorders/differences in sex development. Front Endocrinol (Lausanne) 2024; 15: 1354759
  • 12 Gupta M, Chambers C, O'Flynn O'Brian K. et al. Clitoromegaly in premature infants: is it truly pathologic?. Acad J Ped Neonatol 2021; 10: 555843
  • 13 Izbizky G, Elias D, Gallo A. et al. Prenatal diagnosis of fetal bilateral adrenal carcinoma. Ultrasound Obstet Gynecol 2005; 26: 669-671
  • 14 Bulun SE. Aromatase deficiency. Fertil Steril 2014; 101: 323-329
  • 15 Yami Channaiah C, Memon SS, Sarathi V. et al. 46,XX aromatase deficiency: A single-center experience with the varied spectrum and recurrent variants, and a systematic review of hormonal parameters. Ann Endocrinol (Paris) 2024; 85: 48-55
  • 16 Idkowiak J, Cragun D, Hopkin RJ. et al. Cytochrome P450 Oxidoreductase Deficiency. In: Adam MP, Feldman J, Mirzaa GM et al. (eds) GeneReviews® . Seattle (WA): University of Washington, Seattle; http://www.ncbi.nlm.nih.gov/books/NBK1419/ 1993, accessed 14 October 2024
  • 17 Ben-Chetrit A, Greenblatt EM. Recurrent maternal virilization during pregnancy associated with polycystic ovarian syndrome: a case report and review of the literature. Hum Reprod 1995; 10: 3057-3060
  • 18 Sewer MB, Li D. Regulation of steroid hormone biosynthesis by the cytoskeleton. lipids 2008; 43: 1109-1115
  • 19 Stocco DM, Zhao AH, Tu LN. et al. A brief history of the search for the protein(s) involved in the acute regulation of steroidogenesis. Mol Cell Endocrinol 2017; 441: 7-16
  • 20 Sarafoglou K, Merke DP, Reisch N. et al. Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management. J Clin Endocrinol Metab 2023; 108: 2154-2175
  • 21 Karlekar MP, Sarathi V, Lila A. et al. Expanding genetic spectrum and discriminatory role of steroid profiling by LC-MS/MS in 11β-hydroxylase deficiency. Clin Endocrinol (Oxf) 2021; 94: 533-543
  • 22 Krasowski MD, Drees D, Morris CS. et al. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol 2014; 14: 33
  • 23 Hicks RA, Yee JK, Mao CS. et al. Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia. Metabolomics 2014; 10: 123-131
  • 24 Bacila I-A, Lawrence NR, Badrinath SG. et al. Biomarkers in congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2024; 101: 300-310
  • 25 Lutfallah C, Wang W, Mason JI. et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87: 2611-2622
  • 26 Mermejo LM, Elias LLK, Marui S. et al. Refining hormonal diagnosis of type II 3beta-hydroxysteroid dehydrogenase deficiency in patients with premature pubarche and hirsutism based on HSD3B2 genotyping. J Clin Endocrinol Metab 2005; 90: 1287-1293
  • 27 Claahsen-van der Grinten HL, Speiser PW, Ahmed SF. et al. Congenital adrenal hyperplasia – current insights in pathophysiology, diagnostics, and management. Endocr Rev 2022; 43: 91-159
  • 28 Scott RR, Miller WL. Genetic and clinical features of p450 oxidoreductase deficiency. Horm Res 2008; 69: 266-275
  • 29 Krone N, Hughes BA, Lavery GG. et al. Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 2010; 121: 496-504
  • 30 Krone N, Reisch N, Idkowiak J. et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2012; 97: E257-E267
  • 31 Saraswathy A, Idris A. Ovotesticular disorder of sexual development unmasked by antimüllerian hormone: case report. J ASEAN Fed Endocr Soc 2021; 36: 69-69
  • 32 Lindhardt Johansen M, Hagen CP, Johannsen TH. et al. Anti-Müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol. 2013 2013. 198698
  • 33 Pignatelli D, Carvalho BL, Palmeiro A. et al. The complexities in genotyping of congenital adrenal hyperplasia: 21-hydroxylase deficiency. Front Endocrinol (Lausanne) 2019; 10: 432
  • 34 Anastasovska V, Kocova M. Genotype-phenotype correlation in CAH patients with severe CYP21A2 point mutations in the Republic of Macedonia. J Pediatr Endocrinol Metab 2010; 23: 921-926
  • 35 Araújo RS, Mendonca BB, Barbosa AS. et al. Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007; 92: 4028-4034
  • 36 Araujo RS, Billerbeck AEC, Madureira G. et al. Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation. Clin Endocrinol (Oxf) 62: 132-136
  • 37 Ravichandran L, Paul S, Rekha A. et al Advocating targeted sequential screening over whole exome sequencing in 21-hydroxylase deficiency. Indian J Pediatr Epub 2024; 91: 1-6
  • 38 Syryn H, De Vijver KV, Cools M. Ovotesticular difference of sex development: genetic background, histological features, and clinical management. Horm Res Paediatr 2023; 96: 180-189